Neuroendocrine tumors can be benign or malignant. This condition rarely shows any symptoms and occurs usually in the pancreas, lungs, gastrointestinal tracts, and other organs of the body.  According to the World Health Organization, the incidence of malignant neuroendocrine tumors is 0.2 per 100,000 people. The increased incidence of neuroendocrine tumors (NET) is constantly driving the need for research and therapeutic options. Additionally, there is a keen focus on developing diagnostic devices and technologies. R&D efforts of market players are, therefore, accelerating the market growth over the forecast period of 2019 to 2029. The impact of covid 19 has been really significant impact on the healthcare segment. The pandemic delayed diagnosis and non-emergency and elective surgeries, this led to an increasing queue of patients waiting to avail healthcare solutions. The report details the impact of covid 19 on the NET market in terms of market dynamics and revenues. 

With respect to diagnosis R&D efforts have to novel techniques such as RF ablation technique, Ga labeled radionucleotide therapies. NET-01 chemotherapy for pancreatic tumors, RAD 001 to treat advanced midgut NETs are few examples of therapy techniques that are in the clinical trial stage. Cancer research has been one of the segments that has attracted investment in R&D for the longest time. Apart from research foundations, governments across several countries have been active in cancer research and funding. For instance, in January 2021 The Neuroendocrine Tumor Research Foundation (NETRF) awarded $2.62 million in grants to advanced research focusing on novel treatments for neuroendocrine tumors. In the past 15 years, NETRF has alone invested $30 million on research.

Targeted drug therapy for NET included molecules such as Everolimus and Sunitinib. The targeted therapies are in greater demand as they are efficient in impeding the growth of cancer by targeting the specified molecules that are involved in the growth of cancer. The key advantage of targeted drug therapies is lesser side effects in comparison to chemotherapy. However, some patients are immune to radiation therapy and surgeries, therefore Somatostatin analogues such as Lu-Dotatate and Octreotide remain as an alternative therapy in this case.

The incidence rate in the U.S. for gastrointestinal neuroendocrine neoplasms was about 1.4 cases per 100,000. The healthcare infrastructure in terms of diagnostic centers and drug clearance process through USFDA is very efficient even in case of asymptomatic NET. The rising incidence rate for NET in Europe especially in case of pancreatic NET has a significant impact on the NET drug market. The European Medical Agency provides a supportive regulatory environment. In case of Asia Pacific, the incident rate for NET was 1.5 per 100,000 people. The healthcare infrastructure in APAC is emerging. There has been a significant increase in cancer specialized diagnostic centers and emerging treatment options are expected to boost the NET drugs market during the forecast period of 2023 to 2030.

The report contains a detailed analysis of key market players such as Advanced Accelerator Applications, Novartis AG, Progenics Pharmaceuticals, Inc., Tarveda Therapeutics, Dauntless Pharmaceuticals, Inc., Exelixis, Inc., Hutchinson Medipharma Limited, Ispen. The competitive analysis includes basic profiling, financial performance, product portfolio, pipeline products, recent developments that include strategic partnerships, R&D investment, acquisitions, joint ventures and other key information.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Neuroendocrine Tumor Treatment market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Neuroendocrine Tumor Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Neuroendocrine Tumor Treatment market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Neuroendocrine Tumor Treatment market?
• Which is the largest regional market for Neuroendocrine Tumor Treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Neuroendocrine Tumor Treatment market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Neuroendocrine Tumor Treatment market worldwide?